 Home > Active Ingredient News > Drugs Articles > Novartis 2022Q1｜Nuoxinto medical insurance takes effect, driving a strong growth of 16% in the Chinese market

Novartis 2022Q1｜Nuoxinto medical insurance takes effect, driving a strong growth of 16% in the Chinese market

 Last Update: 2022-05-30
 Source: Internet
 Author: User

Tags

6 3 ground

specification sales

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The financial report for the first quarter of 2022 released by Swiss pharmaceutical giant Novartis (NYSE: NVS) shows that the company's net sales increased by 5% year-on-year (calculated at constant exchange rates, the same below) to $12.

5% Innovative Medicines Sector Sandoz

Source: Novartis Financial Report

The main drivers ofNovartis' innovative business in the quarter were: heart failure drug Nuxinto (sacubitril/valsartan sodium) grew by 42%, and quarterly sales exceeded $1 billion for the first time; autoimmune disease drug Cantilever (secukinumab) up 12%; spinal muscular atrophy drug Zolgensma (Onasemonogene abeparvovec) up 18%; allergic asthma drug Zole (omalizumab) up 17%; breast cancer drug ribociclib ( ribociclib) grew 28%; the recently launched multiple sclerosis drug ofatumumab contributed $195 million

Key drivers of innovative business

Source: Novartis Financial Report

Sales at Novartis ' Innovative Medicines segment rose 3 percent to $3.

Innovative Medicines Sector

Source: Novartis Financial Report

Innocento health insurance takes effect, boosting performance in the Chinese market

Elsewhere, Novartis' emerging markets, including China, were particularly strong , with 12% growth

Emerging markets performed particularly strongly

The reasons include the inclusion of the new indications of Nuoxinto for essential hypertension into the medical insurance from January, and the strong performance of Cosentyx in China

Nuoxintoxanthin _

Source: Novartis Financial Report

Novartis' recent R&D progress includes the approval of Zhuole for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents (12 years and older) who still have symptoms after taking antihistamines, becoming the only biological drug for this indication in China.

Zoloft Filafinitor _

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.